Zentalis Pharmaceuticals, Inc. (ZNTL)
4.105
+0.34
(+8.89%)
USD |
NASDAQ |
Sep 03, 16:00
4.07
-0.04
(-0.85%)
After-Hours: 20:00
Zentalis Pharmaceuticals Cash from Investing (Quarterly) : 30.02M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.02M |
| March 31, 2026 | 30.01M |
| December 31, 2025 | 32.45M |
| September 30, 2025 | 28.32M |
| June 30, 2025 | 30.38M |
| March 31, 2025 | 40.48M |
| December 31, 2024 | 32.28M |
| September 30, 2024 | 48.24M |
| June 30, 2024 | 34.49M |
| March 31, 2024 | 61.54M |
| December 31, 2023 | -42.06M |
| September 30, 2023 | -117.45M |
| June 30, 2023 | 72.93M |
| March 31, 2023 | 42.12M |
| December 31, 2022 | -11.89M |
| Date | Value |
|---|---|
| September 30, 2022 | 20.02M |
| June 30, 2022 | -142.10M |
| March 31, 2022 | 19.80M |
| December 31, 2021 | 43.27M |
| September 30, 2021 | -141.44M |
| June 30, 2021 | 66.60M |
| March 31, 2021 | 13.46M |
| December 31, 2020 | -9.65M |
| September 30, 2020 | -137.89M |
| June 30, 2020 | -118.84M |
| March 31, 2020 | -0.031M |
| December 31, 2019 | -0.036M |
| September 30, 2019 | -0.107M |
| June 30, 2019 | -0.168M |
| March 31, 2019 | -0.041M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | 41.57M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.24M |
| Cash from Financing (Quarterly) | 0.065M |
| Free Cash Flow | -128.13M |
| Free Cash Flow Per Share (Quarterly) | -0.5221 |
| Free Cash Flow to Equity (Quarterly) | -36.28M |
| Free Cash Flow to Firm (Quarterly) | -37.24M |
| Free Cash Flow Yield | -43.75% |